ADHD Medication Adverse Events · Section 2 · Chapter 8 · Blood Pressure and Heart Rate
Sustained Blood Pressure or Heart Rate Rise on ADHD Medication: When to Reduce or Stop?
A 14-year-old on lisdexamfetamine reads 136/84 at a routine visit. An adult on atomoxetine has a resting pulse of 104. A child's reading is high in a rushed clinic and normal when repeated. Stimulants, atomoxetine and viloxazine all raise blood pressure or heart rate, usually a little and sometimes a lot. This chapter covers what the labels report, how to confirm a real rise, when to act, and whether to reduce, switch or stop.
The 30-second version
- What the labels report. The stimulant labels say these drugs raise blood pressure by about 2 to 4 mm Hg and heart rate by about 3 to 6 beats per minute on average, that some patients have larger increases, and that all patients should be monitored for hypertension and tachycardia. In atomoxetine's pediatric trials, controlled and uncontrolled, about 5 to 10% of children had a potentially clinically important rise in heart rate or blood pressure, and viloxazine raises heart rate and diastolic pressure. Guanfacine and clonidine extended-release lower both.
- Confirming a rise. NICE asks for heart rate and blood pressure, measured with an appropriately sized cuff and compared with the normal range for age, before and after each dose change and every 6 months. The AAP grades blood pressure by percentile under age 13 and by adult cutoffs from 13, confirms a high oscillometric reading by auscultation, and diagnoses hypertension only after readings at or above the 95th percentile on 3 different visits. Our view: one high clinic reading is a reason to recheck, not to stop; repeat it rested, ask about caffeine, decongestants and the time of the last dose, and confirm on a second occasion.
- When to act. NICE: if resting heart rate stays above 120 beats per minute, an arrhythmia appears, or systolic pressure is above the 95th percentile (or rises by a clinically significant amount) on 2 occasions, reduce the dose and refer to a pediatric hypertension specialist or adult physician; the percentile applies to children, so in adults the test is a clinically significant rise (our reading). The AAP sends a stage 2 reading with symptoms, or a reading more than 30 mm Hg above the 95th percentile (above 180/120 in an adolescent), to an emergency department. In adults, systolic above 180 or diastolic above 120 with signs of acute organ damage is a hypertensive emergency.
- Reduce, switch or stop. NICE says to reduce the dose. The 2025 US adult guideline lists amphetamines, including lisdexamfetamine, and methylphenidate among drugs that raise blood pressure, and advises stopping them or lowering the dose and considering behavioral therapy or a nonstimulant such as guanfacine. Atomoxetine and viloxazine also raise heart rate and blood pressure, so they are not a reliable way around the problem. When the stimulant is needed or the best option, the US adult guideline considers it reasonable to continue it and start or intensify antihypertensive treatment; we found no trial of this for a stimulant-related rise, so in our view it is a specialist decision.
- Adults and the long term. The US adult guideline classifies blood pressure from the average of at least 2 readings on at least 2 occasions: stage 1 is 130 to 139 systolic or 80 to 89 diastolic, and stage 2 is 140 systolic or 90 diastolic and above. In a Swedish case-control study, 3 to 5 years of ADHD medicine use was associated with higher odds of a hypertension diagnosis than no use (adjusted odds ratio 1.72); an association like this does not prove cause. In 10-year follow-up of children in the MTA study, the authors found no evidence that stimulant treatment increased the risk of hypertension, but heart rate stayed higher while it continued.
At the visit: a high reading on ADHD medicine
About 2 min to read · the detailed chapter follows below
Do now
- Repeat the reading with the right cuff size after the patient has rested.
- Compare it with the baseline reading and with the normal range for age, height and sex.
- Ask about headache, vision change, chest pain, palpitations and fainting.
- Ask about caffeine, energy drinks, decongestants and the time of the last dose.
- Record the drug, dose and the time of the reading after the dose.
Do not
- Stop the medicine on one unconfirmed reading.
- Use the adult cutoffs for a child under 13.
- Switch to atomoxetine or viloxazine expecting a lower pressure.
- Stop guanfacine or clonidine abruptly (Chapter 5).
- Miss symptoms that make a reading an emergency.
Five questions to ask
- What was the reading before treatment? A rise from baseline matters, not just the number.
- Was it measured properly? Cuff size, rest and posture change the reading (our view).
- How long after the dose? In a single-dose study of Adderall XR in adolescents, systolic rises peaked 2 to 4 hours after the dose.
- Any symptoms? Headache, vision change, chest pain or fainting change the urgency.
- Anything else raising it? Caffeine, energy drinks, decongestants, pain and anxiety (our view).
Emergency or same day if any of
- Child or adolescent: a stage 2 reading with symptoms, or more than 30 mm Hg above the 95th percentile (above 180/120 in an adolescent): emergency department (AAP)
- Adult: systolic above 180 or diastolic above 120 with signs of acute organ damage: emergency (US adult guideline)
- Palpitations with chest pain, breathlessness or fainting (Chapter 4)
Reduce the dose and refer if, on 2 occasions
- Sustained resting heart rate above 120 beats per minute
- Child: systolic pressure above the 95th percentile, or a clinically significant rise (NICE; AAP stages use systolic or diastolic)
- Adult: a clinically significant rise; arrange home or ambulatory readings at the same time to confirm hypertension (US adult guideline)
- An arrhythmia
Child at stage 2 without symptoms: recheck within 1 week, or refer to subspecialty care within 1 week (AAP). Adult with confirmed stage 2: lower or stop the stimulant, or, if it is needed, continue it and start or intensify antihypertensive treatment (US adult guideline, Table 11; tying it to stage 2 is our application). Adult with systolic above 180 or diastolic above 120 without organ damage: oral treatment, preferably as an outpatient, without aggressive short-term lowering (US adult guideline, 6.2); lowering or stopping the stimulant as well is our application of Table 11.
Recheck and keep monitoring
One high reading, or a small rise within the label averages: recheck rested with the right cuff, address caffeine and decongestants, and keep measuring before and after each dose change and every 6 months (NICE).
Prescriber-side triage for a raised blood pressure or heart rate on ADHD medicine. Our synthesis of NICE NG87 [12], the AAP pediatric guideline [13] and the 2025 US adult guideline [14], not a validated instrument. The AAP does not define “symptomatic”; its section on acute severe hypertension names encephalopathy, acute kidney injury and heart failure as the acute target organ effects [13]. Our view: count headache, vision change, confusion, chest pain or breathlessness with a stage 2 reading as symptomatic.
Why it gets missed
- No baseline reading on file
- Adult cutoffs applied to a child
- Readings not repeated after a dose increase
- Energy drinks and decongestants not asked about
Before you change the medicine
- Confirm on a second occasion
- Rule out symptoms
- Remove other causes
- Then lower the dose
Look up the situation
Tap the situation for what it means and what to do.
Emergency or same day
Reduce and refer
Recheck and monitor
Very high reading or symptoms
EmergencyAAP: if the reading is at the stage 2 level and the patient is symptomatic, or it is more than 30 mm Hg above the 95th percentile (or above 180/120 mm Hg in an adolescent), refer to an immediate source of care such as an emergency department [13].
What to do
- Send to the emergency department
- Hold the stimulant until reviewed (our view)
- The AAP asks for a prompt search for secondary causes in acute severe hypertension; do not assume the stimulant is the cause [13]
Keep in mind
- Adults: systolic above 180 or diastolic above 120 with acute organ damage is an emergency; without it, reinstitute or intensify oral treatment, preferably as an outpatient, without aggressive short-term lowering [14]; lowering or stopping the stimulant as well is our application of Table 11
- On guanfacine or clonidine, ask about missed doses (Chapter 5)
Fast or irregular pulse with symptoms
Same dayNICE: an arrhythmia on ADHD medicine is a reason to reduce the dose and refer [12]. With chest pain, breathlessness or fainting, follow Chapter 4 (our cross-reference).
What to do
- Follow Chapter 4 for palpitations with symptoms
- ECG when there is a clinical indication [12]
Keep in mind
- NICE: no routine ECG without a clinical indication [12]
- Atomoxetine raises heart rate more in CYP2D6 poor metabolizers [8]
Sustained rise in a child or teen
ReduceNICE: sustained resting heart rate above 120, an arrhythmia, or systolic pressure above the 95th percentile (or a clinically significant increase) on 2 occasions: reduce the dose and refer to a pediatric hypertension specialist [12].
What to do
- Lower the dose and recheck
- Stage 2 without symptoms: recheck or refer within 1 week (AAP) [13]
Keep in mind
- Under 13: percentiles for age, sex and height; from 13: 130/80 is stage 1 [13]
- The AAP lists ADHD stimulants among drugs linked to raised blood pressure in children [13]
Sustained rise in an adult
ReduceThe 2025 US adult guideline lists amphetamines, methylphenidate, dexmethylphenidate and lisdexamfetamine among drugs that raise blood pressure: discontinue or decrease the dose, and consider behavioral therapies or nonstimulants such as guanfacine [14].
What to do
- Lower the dose after a rise on 2 occasions and refer to an adult physician (NICE) [12]
- Arrange home or ambulatory readings to confirm hypertension [14]
- If the stimulant is needed, continuing it while starting or intensifying antihypertensive treatment is reasonable [14]
- Intuniv's ADHD trials were in ages 6 to 17; we found no adult ADHD efficacy data in its label (8.4, 14) [10]
Keep in mind
- Stimulants may reduce the effect of antihypertensive drugs [1][14]
- Stage 1 is 130 to 139 systolic or 80 to 89 diastolic [14]
One high reading, no symptoms, below emergency levels
RecheckNICE: measure with an appropriately sized cuff and compare with the normal range for age; monitor before and after each dose change and every 6 months [12].
What to do
- Repeat after rest, then on another day (our view)
- Ask about caffeine, energy drinks and decongestants (our view)
Keep in mind
- Adderall XR, adolescents: isolated systolic rises of 15 mm Hg or more were seen in 7% on the drug and 11% on placebo [6]
- After a single dose in adolescents, transient systolic rises above the upper 95% limit occurred in 12% at 10 mg and 35% at 20 mg, peaking 2 to 4 hours after the dose and not associated with symptoms [6]
Mild rise on atomoxetine or viloxazine, below action thresholds
MonitorAtomoxetine: in controlled and uncontrolled trials, about 5 to 10% of children had a rise of at least 20 beats per minute or 15 to 20 mm Hg; heart rate rose 9.4 beats per minute in CYP2D6 poor metabolizers against 5 in other metabolizer types. Viloxazine: a rise of at least 20 beats per minute in 22% to 34% of children at some doses, against 9% to 23% on placebo [8][9].
What to do
- If the rise meets the emergency or dose-reduction thresholds above, follow that pathway instead; NICE 1.8.11 covers all ADHD medicines [12]
- Below 120, such as a resting pulse of 104: recheck, ask about symptoms and weigh the rise from baseline (our view)
- Measure after each dose increase [8][9]
Keep in mind
- Atomoxetine is contraindicated in severe cardiac or vascular disorders that would worsen with such a rise [8]
- Neither is a reliable lower-pressure alternative to a stimulant; any switch still needs monitoring
All six situations on one page (figure)
Figure 1. A raised blood pressure or heart rate on ADHD medicine: when to send to the emergency department, when to reduce the dose and refer, and when to recheck and monitor. Adults with systolic above 180 or diastolic above 120 are triaged by signs of acute organ damage (see the triage above). Our summary of NICE NG87, the AAP pediatric guideline and the 2025 US adult guideline [12][13][14].
What the labels report
The stimulant labels say these drugs raise blood pressure by about 2 to 4 mm Hg and heart rate by about 3 to 6 beats per minute on average, that some patients have larger increases, and that all patients should be monitored for hypertension and tachycardia. In atomoxetine's pediatric trials, controlled and uncontrolled, about 5 to 10% of children had a potentially clinically important rise in heart rate or blood pressure, and viloxazine raises heart rate and diastolic pressure. Guanfacine and clonidine extended-release lower both.
| Drug | Blood pressure and heart rate in the labels | Source |
|---|---|---|
| Stimulants (class statement) | Mean rise about 2 to 4 mm Hg and 3 to 6 beats per minute; some patients have larger increases; monitor all patients for hypertension and tachycardia | 5.3 [1][2][3][4][6][7]; warnings [5] |
| Methylphenidate and dexmethylphenidate (Concerta, Focalin XR) | Concerta, children 6 to 12: resting pulse up 2 to 6 beats per minute and blood pressure up 1 to 4 mm Hg against placebo. Adults: standing pulse up 3.9 to 9.8 beats per minute by dose, against 2.7 on placebo. Focalin XR adults: pulse up 3.1, 4.3 and 6.0 at 20, 30 and 40 mg, against −1.4 | 6.1 [1][3] |
| Amphetamines (Vyvanse, Adderall XR) | Vyvanse adults (adverse-reaction rates): increased blood pressure 3% and increased heart rate 2%, against 0%. Adderall XR adolescents: isolated systolic rises of 15 mm Hg or more in 7% against 11% on placebo; in a single-dose study, transient systolic rises above the upper 95% limit in 12% at 10 mg and 35% at 20 mg, largest 2 to 4 hours after the dose | 6.1 [7][6] |
| Atomoxetine (Strattera) | Short-term trials, at any time point: diastolic up 15 mm Hg or more in 22% against 14%, systolic up 20 or more in 13% against 9%, heart rate up 20 or more in 23% against 12% (children); 13% against 9%, 12% against 8% and 22% against 8% (adults). Controlled and uncontrolled trials: about 5 to 10% of children with a rise of at least 20 beats per minute or 15 to 20 mm Hg. At the end of the trials, the shares were lower: 9% against 5%, 5% against 3% and 12% against 4% (children). CYP2D6 poor metabolizers: heart rate up 9.4 against 5 beats per minute in other metabolizer types (children) and 11 against 7.5 (adults). Contraindicated in severe cardiac or vascular disorders expected to worsen with such a rise | 4; 5.4; 6.1 [8] |
| Viloxazine (Qelbree) | Heart rate up at least 20 beats per minute: ages 6 to 11, 22% against 9% (100 mg), 31% against 15% (200 mg), 28% against 23% (400 mg); ages 12 to 17, 22% against 14% (200 mg) and 34% against 17% (400 mg); adults 29% against 13%. Diastolic up at least 15 mm Hg: 25% against 13% (ages 12 to 17, 400 mg); 13% against 9% (adults) | 5.2 [9] |
| Guanfacine extended-release (Intuniv) | Lowers blood pressure and heart rate: maximum mean systolic change −4.3 to −8.2 mm Hg and pulse −3.1 to −8.6 beats per minute across 1 to 4 mg; decreases were less pronounced over time; after a tapered stop, about 3 mm Hg and 5 beats per minute above baseline, returning to baseline in an estimated 6 to 12 months on average in one study | 5.1; 6.1 [10] |
| Clonidine extended-release | Lowers blood pressure and heart rate: maximum placebo-subtracted systolic change −4.0 and −8.8 mm Hg, heart rate −4.0 and −7.7 beats per minute at 0.2 and 0.4 mg/day | 6.1 [11] |
The detail: averages hide the outliers
The stimulant labels give mean changes and then warn that some patients have larger increases [1][7]. The averages come from short trials, and the Adderall XR data show how noisy single readings are: isolated systolic rises of 15 mm Hg or more were as common on placebo as on the drug, while single doses produced transient rises that peaked 2 to 4 hours after the dose [6]. Atomoxetine and viloxazine report the share of patients with large rises rather than means alone, and those shares are higher on the drug than on placebo [8][9]. The AAP ADHD guideline gives average stimulant increases of 1 to 2 beats per minute and 1 to 4 mm Hg, with “more substantial increases in HR and BP in a subset of individuals (5%–15%)” [24]. In a meta-analysis of 18 pediatric trials (5,837 participants), methylphenidate, amphetamines and atomoxetine each produced a small rise in systolic pressure from before to after treatment; amphetamines and atomoxetine also raised diastolic pressure and heart rate, while methylphenidate did not change diastolic pressure or heart rate; the authors note the rises “may be clinically significant for a significant minority of individuals” [16]. In a meta-analysis of 10 adult trials, stimulants raised resting heart rate by 5.7 beats per minute and systolic pressure by 2.0 mm Hg against placebo; a heart rate of 90 or more was more common on stimulants (4.2% against 1.7%), but systolic readings of 140 or more and diastolic readings of 90 or more were not (4.5% to 5.7% across the groups) [17]. A network meta-analysis of 102 short trials found that stimulants did not raise blood pressure or pulse more than atomoxetine or viloxazine, while guanfacine lowered them (abstract only) [18]. Our view: the time of the reading after the dose matters, and the decision should rest on repeated readings against the patient's own baseline.
Confirming a sustained rise
NICE asks for heart rate and blood pressure, measured with an appropriately sized cuff and compared with the normal range for age, before and after each dose change and every 6 months. The AAP grades blood pressure by percentile under age 13 and by adult cutoffs from 13, confirms a high oscillometric reading by auscultation, and diagnoses hypertension only after readings at or above the 95th percentile on 3 different visits. Our view: one high clinic reading is a reason to recheck, not to stop; repeat it rested, ask about caffeine, decongestants and the time of the last dose, and confirm on a second occasion.
| Age | Elevated | Stage 1 | Stage 2 |
|---|---|---|---|
| 1 to under 13 (AAP) | 90th to under 95th percentile, or 120/80 to under the 95th percentile (whichever is lower) | 95th percentile to under 95th + 12 mm Hg, or 130/80 to 139/89 (whichever is lower) | 95th percentile + 12 mm Hg or more, or 140/90 or more (whichever is lower) |
| 13 and older (AAP) | 120/<80 to 129/<80 | 130/80 to 139/89 | 140/90 or more |
| Adults (US 2025) | 120 to 129 and <80 | 130 to 139 or 80 to 89 | 140 or more, or 90 or more |
The detail: getting a reading you can act on
NICE asks for baseline pulse and blood pressure measured with an appropriately sized cuff and compared with the normal range for age, and for monitoring before and after each dose change and every 6 months [12]. The AAP pediatric categories use percentiles for age, sex and height up to age 13, and adult cutoffs from 13 [13]. The US adult guideline bases the category on the average of at least 2 careful readings on at least 2 occasions [14]. Our view: record the time of the reading after the dose, because stimulant effects vary through the day [6], and ask about caffeine, energy drinks, decongestants, pain and anxiety before attributing a rise to the medicine. The AAP says that if an oscillometric reading is high, it should be confirmed by auscultation; that hypertension should be diagnosed after auscultatory readings at or above the 95th percentile on 3 different visits; and that ambulatory monitoring should confirm hypertension when office readings stay elevated for a year or more or at stage 1 over 3 visits [13]. It also asks for blood pressure at every visit in children taking medicines known to raise it [13]. In a crossover trial in 13 children, 24-hour ambulatory monitoring showed higher diastolic pressure (69.7 against 65.8 mm Hg) and heart rate (85.5 against 79.9 beats per minute) on stimulants than on placebo (abstract only) [19]. Our view: NICE's 2 occasions is the trigger to act on the medicine; the AAP steps are the trigger for a hypertension work-up. In adults with suspected hypertension, the US adult guideline recommends out-of-office readings, ambulatory or home, to confirm the diagnosis; it recommends standardized measurement and considers a validated oscillometric device reasonable in preference to auscultation, so the AAP's auscultation step does not carry over to adults [14].
When to act
NICE: if resting heart rate stays above 120 beats per minute, an arrhythmia appears, or systolic pressure is above the 95th percentile (or rises by a clinically significant amount) on 2 occasions, reduce the dose and refer to a pediatric hypertension specialist or adult physician; the percentile applies to children, so in adults the test is a clinically significant rise (our reading). The AAP sends a stage 2 reading with symptoms, or a reading more than 30 mm Hg above the 95th percentile (above 180/120 in an adolescent), to an emergency department. In adults, systolic above 180 or diastolic above 120 with signs of acute organ damage is a hypertensive emergency.
| Finding | Action | Source |
|---|---|---|
| Stage 2 with symptoms, or more than 30 mm Hg above the 95th percentile (above 180/120 in an adolescent) | Immediate source of care, such as an emergency department | AAP 4.3d [13] |
| Adult with systolic above 180 or diastolic above 120 and acute target organ damage | Hypertensive emergency: intensive care admission | US 2025, 6.2 [14] |
| Adult with systolic above 180 or diastolic above 120 without acute target organ damage | Start, restart or intensify oral treatment in a timely manner, preferably as an outpatient; no aggressive short-term lowering or parenteral drugs. Lowering or stopping the stimulant as well is our application of Table 11 | US 2025, 6.2 [14]; our judgment |
| Adult with confirmed stage 2, systolic 180 or below and diastolic 120 or below | Lower or stop the stimulant and consider a nonstimulant; when the stimulant is needed or the best option, continuing it while starting or intensifying antihypertensive treatment is reasonable; refer to an adult physician | US 2025, Table 11 and footnote [14]; NICE 1.8.11 [12]; applying Table 11 at stage 2 is our judgment |
| Sustained resting heart rate above 120, an arrhythmia, or systolic above the 95th percentile (or a clinically significant rise) on 2 occasions | Reduce the dose; refer to a pediatric hypertension specialist or adult physician | NICE 1.8.11 [12] |
| Child at stage 2 without symptoms | Check upper and lower extremity pressures, give lifestyle advice, and repeat within 1 week, or refer to subspecialty care within 1 week | AAP 4.3d [13] |
| Child at stage 1 without symptoms | Lifestyle counseling and recheck in 1 to 2 weeks; if still stage 1, check upper and lower extremity pressures and recheck in 3 months; after 3 visits at stage 1, ambulatory monitoring, evaluation and treatment, and consider referral | AAP 4.3c [13] |
| Child at the elevated level | Lifestyle advice and repeat in 6 months; after 12 months at this level, ambulatory monitoring and evaluation | AAP 4.3b [13] |
The detail: what NICE leaves open
NICE does not define a "clinically significant increase" [12]. The AAP lists central nervous system stimulants among common prescription medicines that raise blood pressure, and says the rise is usually mild and reversible on stopping, but that a significant increase can occasionally occur with higher doses or as an idiosyncratic response [13]. Its follow-up intervals are written for hypertension in general, not for a medicine that can be lowered. The atomoxetine label measures clinically important increases as diastolic up 15 mm Hg or more, systolic up 20 mm Hg or more, or heart rate up 20 beats per minute or more [8]. Our view: use the patient's own baseline, and treat a confirmed move up a stage, or a rise of that size, as clinically significant. NICE also asks for referral before starting ADHD medicine if a child's blood pressure is consistently above the 95th percentile for age and height [12]. Pre-treatment cardiac screening is covered in Psychopharmacology with Cardiac Impairment.
Reduce, switch or stop
NICE says to reduce the dose. The 2025 US adult guideline lists amphetamines, including lisdexamfetamine, and methylphenidate among drugs that raise blood pressure, and advises stopping them or lowering the dose and considering behavioral therapy or a nonstimulant such as guanfacine. Atomoxetine and viloxazine also raise heart rate and blood pressure, so they are not a reliable way around the problem. When the stimulant is needed or the best option, the US adult guideline considers it reasonable to continue it and start or intensify antihypertensive treatment; we found no trial of this for a stimulant-related rise, so in our view it is a specialist decision.
| Option (in order of use, not preference) | What we can say | Basis |
|---|---|---|
| Remove other causes | Caffeine, energy drinks, decongestants; also NSAIDs, alcohol, oral contraceptives, systemic corticosteroids, cocaine and other illicit stimulants, and misuse of the prescribed stimulant (our addition; Chapter 16) | US 2025 Table 11 lists these agents, and advises limiting caffeine to under 300 mg a day and using decongestants for the shortest time possible [14]. The AAP lists caffeine and decongestants among agents associated with raised blood pressure in children [13] |
| Lower the dose | NICE's step once the rise is confirmed on 2 occasions | NICE 1.8.11 [12]; US 2025 [14] |
| Switch to guanfacine extended-release | Lowers blood pressure and heart rate; must be tapered when stopped; Intuniv's ADHD trials were in ages 6 to 17 | US 2025 [14]; Intuniv 5.1, 2.5, 5.4 [10] |
| Switch to atomoxetine or viloxazine | Both raise heart rate and blood pressure; in a network meta-analysis, stimulants did not raise them more than these two | [8][9]; abstract only [18] |
| Add an antihypertensive | Stimulants may reduce its effect. When the stimulant is needed or the best option, the US adult guideline considers it reasonable to continue it and start or intensify antihypertensive treatment. No trial tests this for a stimulant-related rise; one meta-analysis suggests specialist evaluation to consider antihypertensives or beta-blockers and says this needs study. Our view: a specialist decision | Concerta 7 [1]; US 2025 [14]; [20] |
| Stop | When the dose cannot be lowered enough or the rise persists | US 2025 [14]; our judgment |
The detail: switching to an alpha-2 agonist
Guanfacine extended-release lowered seated systolic pressure by up to 8.2 mm Hg and pulse by up to 8.6 beats per minute at 4 mg in its pediatric trials; hypotension was reported in 7% against 3% on placebo [10]. It is licensed as monotherapy and as an adjunct to stimulants [10]. When it is stopped, the dose must be tapered by no more than 1 mg every 3 to 7 days, because blood pressure and pulse can rise above baseline (Chapter 5) [10]. Clonidine extended-release also lowers blood pressure and heart rate [11]. In a 9-week trial in 461 children and adolescents with a partial response to a stimulant, adding guanfacine extended-release produced small mean decreases in pulse and blood pressure against placebo; these children were not hypertensive (abstract only) [22]. In a small open study, 13 adults whose hypertension was already controlled took mixed amphetamine salts extended-release for 6 weeks without a sustained rise (abstract only) [21]. Our view: when the stimulant is working but the pressure is not, a lower stimulant dose plus guanfacine is a reasonable option to discuss with the specialist. Hypotension and bradycardia on these drugs are covered in Chapter 14.
Adults and the long term
The US adult guideline classifies blood pressure from the average of at least 2 readings on at least 2 occasions: stage 1 is 130 to 139 systolic or 80 to 89 diastolic, and stage 2 is 140 systolic or 90 diastolic and above. In a Swedish case-control study, 3 to 5 years of ADHD medicine use was associated with higher odds of a hypertension diagnosis than no use (adjusted odds ratio 1.72); an association like this does not prove cause. In 10-year follow-up of children in the MTA study, the authors found no evidence that stimulant treatment increased the risk of hypertension, but heart rate stayed higher while it continued.
| Question | What we can say | Source |
|---|---|---|
| How is adult hypertension defined? | Average of at least 2 careful readings on at least 2 occasions; stage 1 130 to 139 or 80 to 89; stage 2 140 or 90 and above | US 2025, Table 4 [14] |
| Long-term risk | Hypertension: adjusted odds ratio 1.72 (95% CI 1.51 to 1.97) for 3 to 5 years and 1.80 (1.55 to 2.08) for more than 5 years of use, against no use | Case-control study, Sweden, ages 6 to 64 [15] |
| Adults already on antihypertensives | Stimulants may reduce their effect; monitor blood pressure and adjust the antihypertensive | Concerta 7 [1]; US 2025 [14] |
| Children over years of treatment | MTA: no treatment effect on systolic or diastolic pressure over 10 years; heart rate higher while stimulants continued, and higher with greater cumulative exposure at years 3 and 8 | Long-term follow-up of a randomized trial [23] |
The detail: what the Swedish study shows
In a nested case-control study of 278,027 people aged 6 to 64 in Sweden with an ADHD diagnosis or ADHD medicine, longer cumulative use was associated with a higher risk of cardiovascular disease, mainly hypertension and arterial disease; each additional year of use was associated with a 4% higher risk [15]. The design shows an association, not cause, and does not tell a prescriber which patient will develop hypertension [15]. In the MTA study, “no evidence could be found that stimulant treatment increased the risk for pre-hypertension or hypertension over the 10-year period of observation,” but stimulants “had a persistent adrenergic effect on heart rate if continued”; the measurements were not blinded and methods varied between sites [23]. The two studies differ in design and population, and neither settles the question. Our view: keep measuring for as long as the medicine is taken; this is not a reason to avoid treatment.
Clinical pearls
- No baseline, no comparison.Record pulse and blood pressure before the first dose.
- Under 13, use percentiles.An adult cutoff can miss a child's stage 2 reading.
- One reading is not a trend.Recheck rested, then on another day.
- Ask the time of the dose.Rises can peak hours after it.
- Atomoxetine and viloxazine raise pressure too.They are not a reliable escape route.
- Guanfacine lowers it, but taper it.Never stop it abruptly.
- Pulse above 120 at rest, twice.Reduce and refer (NICE).
Family script & EMR note
Script: a raised reading at a routine visit
"The blood pressure was higher than I'd like today. ADHD medicines can raise it a little, and in some people more, so we check it at every visit. It isn't dangerously high and there are no worrying symptoms, so one reading isn't enough to change the medicine. I'd like to recheck it in a few minutes and again at another visit.
In the meantime, please cut out energy drinks and coffee, and don't use cold medicines with decongestants. If it stays high, the first step is a lower dose.
If [he/she] has a bad headache, blurred vision, chest pain or faints, go to the emergency department."
EMR note: copy, paste and edit
BP / HR ON ADHD MEDICATION Patient: [ ] Age: [ ] Medicine / dose / product: [ ] Time of last dose: [ ] Baseline BP / HR: [ ] Today BP / HR (repeat): [ ] Cuff size / rested: [ ] Category (AAP or adult): [ ] Symptoms: [Y/N] Caffeine / decongestants: [ ] Confirmed on 2 occasions: [Y/N] Plan: [ ] Recheck on: 2026 [ ] Dose reduced to: [ ] [ ] Referred to: [ ] [ ] Switched to: [ ] [ ] ED advised: [Y/N] Clinician: [ ] Date: [ ]
Case (hypothetical): a routine 5-month review
A 14-year-old boy has taken lisdexamfetamine 50 mg each morning for 5 months. Before treatment his blood pressure was 114/70 and his pulse 78. At this visit, measured by auscultation with the right cuff after rest, 3 hours after his dose and with no caffeine that morning, it is 136/84, pulse 98; three weeks ago it was 134/86. He has no headache, chest pain or fainting. He drinks two energy drinks a day. His ADHD is well controlled.
By the end of this chapter you should be able to say what to do.
Case resolution
At 14, the AAP uses adult cutoffs, so these are stage 1-range readings on 2 visits; the AAP diagnoses hypertension only after 3 [13]. In the AAP table for 14-year-old boys, the 95th percentile for systolic pressure is 123 to 134 mm Hg depending on height, so 136 and 134 are at or above it at any height (our reading of the table) [13]. Compared with his baseline, his systolic pressure is up 22 mm Hg today and was up 20 at the earlier visit, which meets the atomoxetine label's 20 mm Hg threshold on both visits; his diastolic pressure was up 16 at the earlier visit (14 today), and his pulse is up 20 today (no pulse was recorded at the earlier visit). We use the label's thresholds as a yardstick (our view) [8]. He has no symptoms, so this is not an emergency. NICE says to reduce the dose and refer when systolic pressure is above the 95th percentile, or rises by a clinically significant amount, on 2 occasions [12]. So, following NICE, lower the lisdexamfetamine (one step, in our view), stop the energy drinks, and refer [12]. Making both changes at the same visit means a lower reading next time cannot be credited to either one; we accept that because NICE's criterion is already met (our view). For a stage 1 reading that persists on a recheck, the AAP's general advice is to check upper and lower extremity pressures and recheck in 3 months, with ambulatory monitoring after 3 visits at stage 1 [13]; because his rise followed the medicine, we would recheck sooner after the dose change (our view). If the pressure stays raised on the lower dose, discuss a nonstimulant such as guanfacine with the specialist, as the US adult guideline suggests for adults [14]. Switching to atomoxetine or viloxazine is not a reliable way to lower his blood pressure, because both can also raise heart rate and blood pressure [8][9]; any switch would still need monitoring.
Why it matters
Every stimulant label warns about blood pressure and heart rate [1][7], and the noradrenergic nonstimulants raise them too [8][9]. Most rises are small, so the risk is overreacting to one reading and stopping a medicine that works, or under-reacting to a sustained rise because no baseline was recorded. Long-term use is associated with a higher rate of diagnosed hypertension [15], so measurement has to continue for as long as treatment does.
References (24)
- Concerta (methylphenidate hydrochloride) extended-release tablets [US prescribing information]. Janssen Pharmaceuticals, Inc. Warnings and precautions (5.3), adverse reactions (6.1) and drug interactions (7). Revised April 2026. Accessed October 2026 via DailyMed. Source type: US product label.
- Ritalin (methylphenidate hydrochloride) tablets [US prescribing information]. Sandoz Inc. Warnings and precautions (5.3). Revised February 2025. Accessed October 2026 via DailyMed. Source type: US product label.
- Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules [US prescribing information]. Novartis Pharmaceuticals Corporation. Warnings and precautions (5.3) and adverse reactions (Table 4). Revised September 2025. Accessed October 2026 via DailyMed. Source type: US product label.
- Daytrana (methylphenidate transdermal system) [US prescribing information]. Noven Therapeutics, LLC. Warnings and precautions (5.3). Revised September 2025. Accessed October 2026 via DailyMed. Source type: US product label.
- Adderall (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate) tablets [US prescribing information]. Teva Pharmaceuticals USA, Inc. Warnings (increased blood pressure and heart rate). Revised May 2024. Accessed October 2026 via DailyMed. Source type: US product label.
- Adderall XR (mixed amphetamine salts) extended-release capsules [US prescribing information]. Takeda Pharmaceuticals America, Inc. Warnings and precautions (5.3) and adverse reactions (hypertension). Revised April 2026. Accessed October 2026 via DailyMed. Source type: US product label.
- Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets [US prescribing information]. Takeda Pharmaceuticals America, Inc. Warnings and precautions (5.3) and adverse reactions (6.1). Revised April 2026. Accessed October 2026 via DailyMed. Source type: US product label.
- Strattera (atomoxetine) capsules [US prescribing information]. Eli Lilly and Company. Contraindications (4), warnings and precautions (5.4) and adverse reactions (6.1, Table 7). Revised June 2026. Accessed October 2026 via DailyMed. Source type: US product label.
- Qelbree (viloxazine) extended-release capsules [US prescribing information]. Supernus Pharmaceuticals, Inc. Warnings and precautions (5.2). Prescribing information revised January 2025; DailyMed SPL revised October 2026. Accessed October 2026 via DailyMed. Source type: US product label.
- Intuniv (guanfacine) extended-release tablets [US prescribing information]. Takeda Pharmaceuticals America, Inc. Indications (1), discontinuation (2.5), warnings and precautions (5.1, 5.4), adverse reactions (6.1), pediatric use (8.4) and clinical studies (14). Revised June 2025. Accessed October 2026 via DailyMed. Source type: US product label.
- Clonidine hydrochloride extended-release tablets [US prescribing information]. Actavis Pharma, Inc. Adverse reactions (effect on blood pressure and heart rate). Revised October 2023. Accessed October 2026 via DailyMed. Source type: US product label (generic twice-daily ADHD tablet).
- National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline NG87. Published March 2018; last updated September 2019. Recommendations 1.7.4, 1.7.6, 1.8.9, 1.8.10 and 1.8.11 read. Accessed October 2026. Source type: UK national clinical guideline.
- Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3):e20171904. doi:10.1542/peds.2017-1904. Key action statements 2, 3, 5 and 6, Tables 3, 8 and 11, sections 4.3a to 4.3d, 5.7 and 11.1 read in full text. Source type: US clinical practice guideline (American Academy of Pediatrics).
- Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2025;86(18):1567–1678. doi:10.1016/j.jacc.2025.05.007. Sections 3.1.1, 3.1.3, 3.1.4 and 6.2, Table 4, Table 11 and its footnote, and the drug-interaction table read in full text. Source type: US multisociety clinical practice guideline.
- Zhang L, Li L, Andell P, et al. Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry. 2024;81(2):178–187. doi:10.1001/jamapsychiatry.2023.4294. Read in full text (PMC10851097). Source type: peer-reviewed nested case-control study of Swedish registers.
- Hennissen L, Bakker MJ, Banaschewski T, et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs. 2017;31(3):199–215. doi:10.1007/s40263-017-0410-7. Read in full text (PMC5336546). Source type: systematic review and meta-analysis.
- Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. Eur Neuropsychopharmacol. 2013;23(6):534–541. doi:10.1016/j.euroneuro.2012.06.011. Read in full text (author manuscript, PMC3488604). Source type: meta-analysis of randomized trials.
- Farhat LC, Lannes A, Del Giovane C, et al. Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2025;12(5):355–365. doi:10.1016/S2215-0366(25)00062-8. Erratum in Lancet Psychiatry. 2025;12(7):e12. Abstract only. Source type: systematic review and network meta-analysis.
- Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006;21(1):92–95. doi:10.1007/s00467-005-2051-1. Abstract only. Source type: randomized crossover trial.
- Liang EF, Lim SZ, Tam WW, et al. The effect of methylphenidate and atomoxetine on heart rate and systolic blood pressure in young people and adults with ADHD: systematic review, meta-analysis, and meta-regression. Int J Environ Res Public Health. 2018;15(8):1789. doi:10.3390/ijerph15081789. Read in full text (PMC6121294). Source type: systematic review and meta-analysis.
- Wilens TE, Zusman RM, Hammerness PG, et al. An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension. J Clin Psychiatry. 2006;67(5):696–702. doi:10.4088/jcp.v67n0502. Abstract only. Source type: open-label study (13 adults).
- Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74–85.e2. doi:10.1016/j.jaac.2011.10.012. Abstract only. Source type: randomized controlled trial.
- Vitiello B, Elliott GR, Swanson JM, et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry. 2012;169(2):167–177. doi:10.1176/appi.ajp.2011.10111705. Read in full text (author manuscript, PMC4132884). Source type: long-term follow-up of a randomized trial.
- Wolraich ML, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528. doi:10.1542/peds.2019-2528. Read in full text (PMC7067282). Source type: US clinical practice guideline (American Academy of Pediatrics).
Last reviewed October 2026. Part of the Psychiatry Education Forum Academy, Managing ADHD Medication Adverse Events · Section 2 · Chapter 8.
Next: Chapter 9
Anxiety or panic on a stimulant: reduce, change or stop?
This chapter is educational material for licensed prescribers and prescribers in training. It is not a substitute for clinical judgment, local protocols or the current prescribing information. Psychiatry Education Forum Academy is not a CME provider and this chapter does not carry CME credit.
Responses